Q32 Bio Inc. (QTTB) Liabilities and Shareholders Equity (2017 - 2026)

Q32 Bio has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $115.9 million in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 75.25% year-over-year to $115.9 million in Q2 2026; TTM through Jun 2026 was $299.1 million, a 12.56% decrease from a year earlier, with the FY2025 full-year figure at $61.8 million, down 33.09% from the prior year.
• Liabilities and Shareholders Equity was $115.9 million for Q2 2026 at Q32 Bio, up from $63.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $311.0 million in Q1 2022, with the low at $47.1 million in Q4 2023.
• Average Liabilities and Shareholders Equity over 5 years is $142.2 million, with a median of $120.0 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity plunged 79.4% in 2023, then soared 96.21% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $228.5 million in 2022, then slumped by 79.4% to $47.1 million in 2023, then soared by 96.21% to $92.3 million in 2024, then slumped by 33.09% to $61.8 million in 2025, then soared by 87.56% to $115.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $115.9 million (Q2 2026), $63.7 million (Q1 2026), and $61.8 million (Q4 2025), per Business Quant data.